The price of Kodiak Sciences Inc. (NASDAQ:KOD) shares last traded on Wall Street fell -7.98% to $3.63.
Based on available information, 6 analysts follow Kodiak Sciences Inc. (NASDAQ:KOD). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $2.00, we find $5.00. Given the previous closing price of $3.94, this indicates a potential upside of 26.9 percent. KOD stock price is now -48.49% away from the 50-day moving average and -46.30% away from the 200-day moving average. The market capitalization of the company currently stands at $184.59M.
Among analysts, 3 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $6.75 as their price target over the next twelve months.
In other news, BORGESON JOHN A., insider sold 2,749 shares of the company’s stock on Jun 16. The stock was sold for $25,373 at an average price of $9.23. Upon completion of the transaction, the insider now directly owns 178,077 shares in the company, valued at $0.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 16, EHRLICH JASON sold 2,258 shares of the business’s stock. A total of $20,841 was realized by selling the stock at an average price of $9.23. This leaves the insider owning 61,924 shares of the company worth $0.22 million. Insiders disposed of 67,587 shares of company stock worth roughly $0.25 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KOD stock. A new stake in Kodiak Sciences Inc. shares was purchased by BRUCE & CO., INC. during the first quarter worth $1,717,000. IKARIAN CAPITAL, LLC invested $590,000 in shares of KOD during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in Kodiak Sciences Inc. valued at approximately $502,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in KOD for approximately $207,000. BOOTHBAY FUND MANAGEMENT, LLC purchased a new stake in KOD valued at around $121,000 in the second quarter. In total, there are 206 active investors with 81.40% ownership of the company’s stock.
A candlestick chart of Kodiak Sciences Inc. (NASDAQ: KOD) showed a price of $3.7400 on Tuesday morning. During the past 12 months, Kodiak Sciences Inc. has had a low of $2.77 and a high of $12.80. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.30, and a quick ratio of 6.30. The fifty day moving average price for KOD is $7.0482 and a two-hundred day moving average price translates $6.7604 for the stock.
The latest earnings results from Kodiak Sciences Inc. (NASDAQ: KOD) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$1.35, missing analysts’ expectations of -$1.33 by -0.02. This compares to -$1.83 EPS in the same period last year. The company reported revenue of $74.61 million for the quarter, compared to $95.77 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -22.09 percent.
Kodiak Sciences Inc.(KOD) Company Profile
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
